FDA approves expanded indication for medical device to treat a form of brain cancer

The U.S. Food and Drug Administration today approved an expanded indication for the Optune device to treat patients with newly-diagnosed glioblastoma multiforme (GBM), an aggressive form of brain cancer. It is given along with the chemotherapy drug temozolomide (TMZ) following standard treatments that include surgery, chemotherapy, and radiation therapy.

FDA approves expanded indication for medical device to treat a form of brain cancer

The U.S. Food and Drug Administration today approved an expanded indication for the Optune device to treat patients with newly-diagnosed glioblastoma multiforme (GBM), an aggressive form of brain cancer. It is given along with the chemotherapy drug temozolomide (TMZ) following standard treatments that include surgery, chemotherapy, and radiation therapy.

K-9 Kraving Dog Food Has Announced a Voluntary Recall of Their Chicken Patties Dog Food Shipped Between July 13th – July 17th, 2015 Because The Product May Be Contaminated With Salmonella and Listeria monocytogenes

K-9 Kraving Dog 13th – July 17th, 2015 because these products may be contaminated with Salmonella and Listeria Food has announced a voluntary recall of their Chicken Patties Dog Food shipped between July Monocytogenes. Salmonella and Listeria Monocytogenes can affect animals eating the products and there is risk to humans from handling contaminated pet products, especially if they have not thoroughly washed their hands after having contact with the products or any surfaces exposed to these products.

Texas Star Nut and Food Co., Inc. Voluntarily Recalls Natural Macadamia Nuts and Simply Raw Trail Mix Due To Possible Salmonella Contamination

Texas Star Nut and Food Co., Inc. VOLUNTARILY RECALLS Nature’s Eats, Natural Macadamia Nuts 6oz and Southern Grove, Simply Raw Trail Mix 8oz. The above products have the potential to be contaminated with Salmonella, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems.

FDA approves Keytruda for advanced non-small cell lung cancer

The U.S. Food and Drug Administration today granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments and with tumors that express a protein called PD-L1. Keytruda is approved for use with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, the first test designed to detect PD-L1 expression in non-small cell lung tumors.